Hegseth Orders Mandatory Testosterone Testing for Most Male Troops Over 30/ TezzBuzz/ WASHINGTON/ J. Mansour/ The Pentagon has issued formal guidance requiring testosterone screening for male service members age 30 and older, while allowing younger troops to request testing. Treatment will remain voluntary, and the guidance acknowledges that testosterone therapy has limited proven benefits and could reduce fertility. Medical experts question routine screening of people without symptoms, while the Pentagon argues the program could improve health and military readiness.
Quick Look
- Male service members age 30 and older will undergo testosterone screening.
- Younger male troops can request testing.
- The current guidance does not apply to female service members.
- A separate clinical guideline for women remains under review.
- Testosterone replacement therapy will not be mandatory.
- The policy recognizes possible benefits for sexual function and bone density.
- Pentagon guidance says evidence does not support therapy for improving energy or cognition.
- Military doctors should not prescribe it to personnel planning to have children soon.
- Testosterone’s controlled-substance status creates deployment and supply challenges.
- Medical organizations generally recommend testing symptomatic patients rather than universal screening.
Deep Look
Pentagon formalizes mandatory testosterone screening
WASHINGTON — The Pentagon is moving forward with mandatory testosterone testing for male service members age 30 and older, despite questions from medical experts about whether routine screening is necessary or supported by available evidence.
Clinical guidance released Thursday explains how the military will screen personnel for testosterone deficiency and when doctors may consider replacement therapy.
Defense Secretary Pete Hegseth announced the initiative in July, arguing that identifying hormone deficiencies could help troops perform at their “absolute best.”
The screening requirement will apply automatically to male personnel beginning at age 30. Younger male service members will also be permitted to request testing.
The new policy formalizes a program that Hegseth first announced in July as part of a broader military-readiness initiative.
Women excluded from initial guidance
Hegseth’s original July directive called for mandatory testosterone-deficiency screening across the armed forces without limiting the order to men.
The clinical document released Thursday narrows the initial program, stating that it addresses “testosterone deficiency in the male service member.”
Female troops are not currently included.
The guidance says “the female clinical practice guideline is being reviewed and will be posted upon approval.”
The Pentagon has not explained whether the future guidelines will allow women approaching menopause to receive evaluations for estrogen-based treatment or other hormone therapies.
The difference between the original directive and the new guidance leaves unanswered questions about when the military will establish comparable screening standards for female service members.
Pentagon links hormone health to readiness
Pentagon spokesperson Sean Parnell said the initiative is intended to identify health conditions that could affect troops’ performance.
“By proactively identifying and treating suboptimal hormone levels,” the Pentagon aims to “invest in the health of its warfighters, strengthen their performance, and maximize force readiness,” Parnell said.
Hegseth has presented hormone evaluation as part of an effort to improve physical and psychological readiness across the force.
His July memorandum directed the Pentagon to develop a screening program and expand access to treatment for troops diagnosed with a deficiency.
The policy arrives amid growing popular interest in testosterone replacement, particularly among men seeking increased strength, energy or a more youthful feeling.
Medical experts caution that many broad claims promoted by health influencers and podcasters have not been established by clinical evidence.
Policy departs from usual screening recommendations
Testosterone levels naturally decline as men age. Low levels may affect sexual function, mood, bone density and other aspects of health.
Diagnosing a medical deficiency can be complicated because hormone levels fluctuate and symptoms may have several possible causes.
Most medical organizations do not recommend automatic testosterone screening for all men in a particular age group. Standard guidelines generally advise doctors to evaluate patients who report relevant symptoms, such as reduced libido or depressed mood.
A diagnosis usually requires both symptoms and two separate blood tests showing low hormone levels.
The Pentagon policy differs by ordering screening for all male troops age 30 and older, regardless of whether they have reported symptoms.
Aside from that automatic testing requirement, much of the guidance follows conventional medical standards for diagnosis and treatment.
Pentagon acknowledges limited proven benefits
The clinical document recognizes that testosterone replacement is not supported as a general method for increasing energy, mental sharpness or physical performance.
“Evidence does not support its use to improve energy, vitality, physical function, or cognition,” the guidelines state.
Instead, the document identifies “demonstrated benefits” involving sexual function and certain physical measures, including bone density.
Federal research conducted during the past decade has found that testosterone treatment can improve low libido, erectile dysfunction and related problems in men who have clinically low hormone levels.
Those findings are narrower than claims that the therapy broadly improves energy, muscle development, mood or battlefield performance.
Treatment remains voluntary
A service member who meets the Pentagon’s diagnostic requirements will not be required to begin testosterone replacement therapy.
The policy makes screening mandatory for the covered male population, but treatment decisions will remain voluntary and subject to consultation with military medical professionals.
Doctors must discuss possible side effects and assess whether therapy is appropriate for the individual patient.
The guidelines also recognize that treatment may require long-term monitoring and reliable access to medication—requirements that can become more complicated during deployments.
Fertility risks receive prominent warning
One of the most significant known effects of external testosterone is a reduction in sperm production.
When testosterone enters the body through injections, gels or other medications, the body may reduce or stop its natural production. That response can cause sperm counts to fall and affect fertility.
Military physicians are therefore instructed not to prescribe testosterone replacement to service members who plan to have children in the near future.
The policy’s fertility warning is especially relevant to a military population that includes many younger adults who may be planning families.
Controlled-substance rules complicate deployments
Testosterone is a federally controlled substance, creating additional logistical and regulatory issues for deployed troops.
The guidance states that its “use in the deployed environment raises supply, custody, storage, and continuity considerations that should be resolved before departure rather than in theater.”
Injectable testosterone “requires controlled room temperature storage and controlled substance accountability,” according to the document.
Service members using replacement therapy must arrange an adequate supply before deployment. Federal prescription limits for controlled substances could complicate efforts to maintain continuous treatment during extended assignments.
Medical personnel must also ensure that the medication can be stored securely and at the required temperature.
Guidance contrasts with Hegseth’s broader claims
The caution contained in the clinical guidelines contrasts with Hegseth’s more expansive public argument for testosterone treatment.
In July, he said the conditions of modern warfare require “maximum psychological and mental readiness” and presented testosterone therapy as one potential part of improving troop performance.
The final medical guidance is more restrained. It emphasizes established clinical benefits, recognizes side effects and warns that the treatment is not proven to improve energy, cognition or general physical function.
The difference reflects the separation between the policy’s readiness-focused messaging and the narrower evidence considered by military medical professionals.
Questions over science and implementation remain
The Pentagon must now implement routine testing across a large population of male service members while developing separate guidance for women.
Outstanding questions include how frequently troops will be tested, how the services will manage follow-up appointments and how treatment will be maintained during overseas deployments.
Medical experts are also likely to continue debating whether testing all male troops over 30 provides meaningful health benefits compared with evaluating only those who report symptoms.
The Pentagon maintains that early identification can improve troop health and readiness. Critics argue that universal screening risks encouraging unnecessary treatment for naturally changing hormone levels.
More on US News